[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sahlgrenska University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":663},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,53,0,25,[9,48,75,109,137,164,191,217,240,261,289,313,333,354,376,413,444,470,498,519,542,566,591,621,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100633278","implementing-an-evidence-based-standardized-care-bundle-targeting-register-nurses-and-anaesthesiologists-to-enhance-patient-safety-and-quality-of-intravascular-access-devices-care-management---the-safe-ivads-project-a-longitudinell-implementation-intervention-with-an-embedded-process-evaluation-100633278",false,"NCT07524608","Implementing an Evidence-based, Standardized Care Bundle Targeting Register Nurses and Anaesthesiologists, to Enhance Patient Safety and Quality of Intravascular Access Devices Care Management - The Safe-IVADs Project. A Longitudinell Implementation Intervention With an Embedded Process Evaluation.","The Safe IVADs Project","Inclusion Criteria:\n\n* Register nurses and anesthesiologist\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":20,"type":21},700,"ESTIMATED","OBSERVATIONAL","The goal of this observational study spanning over three years is to evaluate the effectiveness of implementing a co-designed, care bundle on intravascular access device (IVAD) quality and nurses and anaesthesiologist knowledge of IVADs best practices, at an intervention hospital compare to care as usual the a control hospital. Additional aims are to:\n\n1. translate and validate a tool for identifying patients with difficult vein access within the Swedish healthcare context,\n2. to evaluate the implementation related to its feasibility, acceptability, fidelity, and cost-effectiveness.\n\nThe main questions it aims to answer are:\n\n* Does the implementation of evidence-based practices improve the quality of IVADs care, e.g. thrombophlebitis\u002Fphlebitis, extravasation, infiltration, dislodgement and increase register nurses and anaesthesiologists' knowledge of IVADs best practices?\n* Does the intervention bridge barriers to successful implementation and support routinization of evidence-based practices.\n* Which factors influence the implementation in terms of feasibility, acceptability, cost-effectiveness and compatibility with professionals' existing values and clinical workflows?",[25,26,27,28,29],"Phlebitis","Thrombophlebitis","Infiltration of Peripheral IV Therapy","Extravasation Injury","Infections Symtoms",[31,32,33,34],"Quality of intravascular catheters","Quality of peripheral vein cathters","Point prevalence measure of quality of intravascular catheter","Implementation intervention","NOT_YET_RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":21},"2026-07-20",{"date":43,"type":21},"2028-12-31",{"name":45,"class":46},"Sahlgrenska University Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100642990","feasibility-study-of-up-a-ast-parent-group-for-adolescents-with-autism-and-co-occurring-anxietydepression-100642990","NCT07637799","Feasibility Study of UP-A-AST Parent Group for Adolescents With Autism and Co-occurring Anxiety\u002FDepression","Unified Protocol-Adolescent Autism Parent Group (UP-A-AST) for Adolescents With Autism Spectrum Disorder and Co-occurring Anxiety and\u002For Depressive Disorders: A Feasibility Study","Inclusion Criteria:\n\n* Adolescents aged 12-17 years\n* Clinical diagnosis of autism spectrum disorder (ASD) according to DSM-IV, DSM-5, or ICD-10\n* Current diagnosis of anxiety disorder and\u002For depressive disorder according to DSM-5\n* Ongoing contact with a Child and Adolescent Psychiatry (BUP) outpatient clinic\n* Stable psychopharmacological treatment at the time of inclusion (if applicable)\n* Parents has participated in a psychoeducational program on autism within child and adolescent psychiatric services, or is assessed by the clinician to have equivalent knowledge\n\nExclusion Criteria:\n\n* Presence of a severe psychiatric disorder, such as psychotic disorder, bipolar disorder, or severe eating disorder\n* High suicide risk or suicide attempt within the past 12 months\n* Severe self-injurious behavior\n* Intellectual disability according to DSM-5\n* The adolescent is primarily in need of basic interventions for autism spectrum disorder\n* Parents are unable to attend all group sessions and\u002For lack the ability to engage in assigned home practice\n* Need for an interpreter","12 Years",{"count":57,"type":21},72,"INTERVENTIONAL",[60],"NA","Autism spectrum disorder (ASD) is associated with high rates of psychiatric comorbidity, particularly anxiety and depressive disorders, which contribute to significant impairment for affected youth and their families. Although cognitive behavioral therapy (CBT) is recommended as a first-line treatment for anxiety and depression in children and adolescents, there is a lack of evidence-based interventions specifically adapted for youth with ASD and co-occurring emotional disorders.\n\nThe Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C\u002FUP-A) is a CBT-based intervention targeting shared mechanisms underlying anxiety and depression. A parent-mediated adaptation, the Unified Protocol-Adolescent Autism Parent Group (UP-A-AST), has been developed to address the specific needs of adolescents with ASD and co-occurring anxiety and\u002For depressive disorders. Preliminary quality improvement work has shown promising results.\n\nThis study aims to evaluate the feasibility, acceptability, and preliminary effects of the UP-A-AST Parent Group in a child and adolescent outpatient psychiatric setting. The study will include parents of adolescents aged 12-17 years with ASD and co-occurring anxiety and\u002For depressive disorders. Outcomes include changes in adolescents' psychiatric symptoms and functional impairment, as well as parents' perceived parenting competence. Additionally, parents' experiences of participating in the intervention will be explored.",[63,64,65],"Autistic Spectrum Disorder","Anxiety Disorders","Depressive Disorder","RECRUITING","2026-06-09",{"date":69,"type":39},"2026-06-10",{"date":71,"type":39},"2026-01-05",{"date":73,"type":21},"2027-03-30",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":58,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":47},"100643703","bedside-assessment-of-right-ventricular-output-lying-in-prone-or-supine-position-100643703","NCT07632027","Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine Position","The BAROLO Study Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine Position. Hemodynamic Changes Due to Prone Position in Patients After Cardiac Surgery - a Prospective Randomized Controlled Trial Evaluating the Effect of Prone Position on Right Heart Function","BAROLO","Inclusion Criteria:\n\n* Scheduled for cardiac surgery using cardiopulmonary bypass\n\nExclusion Criteria:\n\n* BMI \\>40\n* Emergency surgery\n* In need of secondary surgery\n* Advanced grown up congenital heart disease\n* Pulmonary disease\n* Hemodynamic instability with Norepinephrine \\>0.4mcg\u002Fkg\u002Fmin\n* Any condition which, in the judgement of the investigator, might increase the risk to the patient",{"count":84,"type":21},80,[60],"Right ventricular failure (RVF) is a common complication to cardiac surgery, which is associated to mortality, kidney failure, stroke, prolonged mechanical ventilation and ICU stay. The right ventricle is particularly vulnerable to an increased afterload. By increasing pulmonary vascular resistance (PVR), atelectasis might mitigate a negative effect on the right ventricle.\n\nRecruitment maneuvers have been shown to resolve atelectasis and improve hemodynamics by increasing cardiac output and lowering PVR. However these maneuvers transiently raise airway pressures, which in turn increases right ventricular afterload, a situation often poorly tolerated by patients with RVF.\n\nProne position is used in patients with respiratory failure and has been shown to decrease mortality in patients with ARDS. Prone position decreases atelectasis and moves ventilation dorsally. In ARDS it also seems to mediate beneficial hemodynamic effects such as an increase in cardiac output and a decrease in PVR.\n\nThe investigators hypothesis is that prone position early after cardiac surgery will increase cardiac output by recruitment of atelectasis and thereby decrease PVR.",[88,89,90,91,92,93,94,95,96,97,98,99,100],"Right Ventricular Function","Prone Position","Atelectasis","Atelectases, Postoperative Pulmonary","Cardiac Output","Vasoconstriction","Heart Failure","Recruitment Maneuver","Respiratory Mechanics","Pulmonary Arterial Pressure","Cardiac Surgery","Cardiac Surgery Recovery","Cardiopulmonary Bypass","2026-06-03",{"date":103,"type":39},"2026-06-08",{"date":105,"type":21},"2026-09",{"date":107,"type":21},"2028-10",{"name":45,"class":46},{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":58,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":47},"100640097","probiotics-and-biomarkers-in-irritable-bowel-syndrome-100640097","NCT07584278","Probiotics and Biomarkers in Irritable Bowel Syndrome","The Impact of Probiotics on Biomarkers and Symptom Severity in Irritable Bowel Syndrome","BIO-IBS","Inclusion Criteria:\n\n* Diagnosed with IBS according to ROME V criteria\n* IBS-SSS greater than or equal to 75\n* Adult over 18 years old\n* BMI 18.5-35 kg\u002Fm2\n* Able to understand the participant information sheet and willing to comply with the study protocol\n* Able to give informed consent\n* Able to complete the Swedish questionnaires\n\nExclusion Criteria:\n\n* History of any gastroenterology disease including coeliac disease, heart, liver, neurological, or current psychiatric disease, diabetes, any surgery to the abdomen that affects intestinal function (not including cholecystectomy, appendectomy, ceasarean section).\n* The use of opioids 1 month prior to screening and throughout the study\n* The use of probiotic supplements from 14days before randomization and during the study (not including foods with probiotic components)\n* Consumption of antibiotics 3 months prior to screening and throughout the study\n* The start of any new drugs that affect the gastrointestinal tract or symptoms within the last month before the start of the study. As well as the start of new diets of psychological therapy as treatment for IBS symptoms.\n* Participation in any medical research during the last month\n* Clinically relevant lab abnormalities at the time of screening (fecal calprotectin greater than or equal to 150 ug\u002Fg as absolute cutoff. If calprotectin is between 50 - 150ug\u002Fg the decision is made on clinical judgement)\n* Pregnancy, plan to become pregnant during the study, breastfeeding\n* alcohol consumption \\>14 units per week\n* Use of recreational active drugs during 1 month before screening or during the study\n* Use of medication that primarily affects bowel function, transit time, stool consistency 2 weeks before the intervention or during the 12 week intervention period",{"count":118,"type":21},252,[60],"The goal of this double-blind parallel-arm randomized controlled trial is to learn if a probiotic supplement (containing a new strain derived from L. reuteri) alters outcomes related to symptom severity and transit time in adults with irritable bowel syndrome (IBS). The main question it aims to answer is:\n\nDoes the probiotic alter IBS symptom severity?\n\nResearchers will compare the probiotic to a placebo (a lookalike substance that contains no probiotic) to see if the probiotic works to alter outcomes.\n\nParticipants will:\n\nBe randomized to either take the probiotic supplement or placebo supplement daily for 12 weeks.\n\nVisit the lab for 4 study visits (visit 1: screening and informed consent; visit 2: randomization, data collection, beginning the intervention; visit 3: end of intervention and data collection; visit 4: 3 month post intervention follow up and data collection).\n\nProvide biological samples (blood, stool, saliva, urine) Complete questionnaires",[122],"Irritable Bowel Syndrome (IBS)",[124,125,126,127,128],"probiotic","irritable bowel syndome","ibs symptom severity","oro-anal transit time","randomized controlled trial","2026-05-27",{"date":131,"type":39},"2026-06-01",{"date":133,"type":39},"2026-04-28",{"date":135,"type":21},"2031-05",{"name":45,"class":46},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":147,"studyType":22,"phases":4,"briefSummary":148,"conditions":149,"keywords":154,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},"100638245","venous-resection-in-patients-undergoing-pancreatic-surgery-100638245","NCT07621029","Venous Resection in Patients Undergoing Pancreatic Surgery","Perioperative Factors Linked to Increased Risk for Thrombosis During Pancreatectomy With Venous Resection: the Influence of Technical Factors and Perioperative Antithrombotic Prophylaxis.","VENUS","Inclusion Criteria:\n\n* Patients undergoing curative pancreatic resection with simultaneous PV\u002FSMV resection; Any final pathology; Date of pancreatic surgery June 1st, 2026 - June 30th, 2027 (prospectively)\n\nExclusion Criteria:\n\n* Distant metastases (M1); Age \\\u003C18 years; R2 resection",{"count":146,"type":21},1000,"6 Months","Pancreatic surgery is the only treatment in the multimodality approach to pancreatic cancer sine qua non long-term survival cannot be achieved. Pancreatectomy with vein resection (PVR) of the portal vein and the superior mesenteric vein (PV\u002FSMV) to address tumors with venous infiltration has become standard of care in pancreatic surgery for the past 20 years. Larger series and meta-analyses show that long-term survival beyond the 5-year threshold can be achieved with PVR, but with somewhat inferior survivor compared to standard pancreatic resections without venous resection. That is most likely due to the fact that tumors necessitating PVR are generally larger, less differentiated, and more likely to express unfavourable features such as perineural infiltration.\n\nRecent publications point out that PVR can be performed in pancreatic centers around the world with comparable morbidity and mortality, irrespective of the countries' income status. Also, benchmark outcomes for PVR in low-risk patients have been established, defining that the accepted risk for venous thrombosis should be lower than 14% at discharge. Despite that, a questionnaire among expert surgeons reveals that even if PVR is considered a standard procedure, surgeons are still concerned about significant morbidity. Also, the perception as to what proportion of patients require venous resection, how it should be performed and what anti-thrombotic prophylaxis should be given varies widely. The reported morbidity and thrombosis rates after different types of venous resections and reconstructions vary from under 2 to over 25%. There is no consensus as to which type of venous reconstruction is associated with most favourable short- and long-term outcomes, what specific surgical manoeuvres and graft materials decrease the overall complication and the vein-resection specific complications rates and what anti-thrombotic prophylaxis is safest (associated with lowest thrombosis rates and bleeding complications). Although some studies suggest that grafts are associated with higher thrombosis rates, there is no profound investigation as to how to avoid the use of grafts or, if necessary, what grafts are associated with least thrombotic risks while not causing increased patient morbidity.\n\nThe purpose of this study is to evaluate different technical manoeuvres, anti-thrombotic prophylaxis strategies and organisational features in a large cohort of patients undergoing PVR in median and large-volume centers in order to assess which factors contribute to vein resection-related specific morbidity.\n\nThe study design is an international multi-center observational cohort study, with retrospective and prospective part, including patients who underwent pancreatic surgery with PV\u002FSMV resection from 2018 to June 30 th 2025 and prospectively 18 months ahead. Perioperative factors, related to technical decisions, perioperative resuscitation, institutional organisational specificities, and anti-thrombotic prophylaxis, associated with increased risk for early (30-day), intermediate 30 days-6 months and late venous thrombosis (\\>6months) will be analysed. The thrombosis rate among the four types of venous reconstructions will be compared while adjusting for the length of the resected vein segment. Median and high-volume pancreatic centers (\\>20 pancreatic resected \u002Fyear).\n\nThe inclusion criteria are: patients undergoing radical pancreatic resection with simultaneous PV\u002FSMV resection, irrespective of final pathology operated between January 1 st 2018 - June 30 th, 2025 (retrospectively) or from July 1 st 2025-December 30 th, 2026 (prospectively). Patients with distant metastases (M1), \\\u003C18 years of age or undergoing R2 resection will be excluded.\n\nThe study intends to include over 1000 patients. The main objective is to assess the perioperative factors (technical, organisational, anti-thrombotic treatment) associated with increased risk for early (30 days), intermediate (\\>30 days-6 months) and late (\\>6 months) venous thrombosis.",[150,151,152,153],"IPMN, Pancreatic","Pancreatic Cancer, Resected","Pancreatic Cancer Borderline","Chronic Pancreatitis",[155,156],"Pancreatic surgery","Venous resection",{"date":158,"type":39},"2026-06-02",{"date":131,"type":21},{"date":161,"type":21},"2027-12-31",{"name":45,"class":46},2,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":58,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100637720","comparing-two-skin-incisions-for-flexor-tendon-repair-100637720","NCT07596017","Comparing Two Skin Incisions for Flexor Tendon Repair","Prospective Randomized Controlled Trial to Compare Bruner Incision With Modified Midlateral Bruner Incision for Flexor Tendon Repair","Inclusion Criteria:\n\n* flexor tendon injury in the hand in zone 2\n\nExclusion Criteria:\n\n* complex injuries with fracture and\u002For skin defect\n* previous injury with functional deficit of the finger or the contralateral control finger\n* incapable to follow the training protocol for flexor tendon injuries\n* not proficient in swedish or english language\n* active substance abuse",{"count":172,"type":21},70,[60],"Flexor tendons injuries in the fingers are common and often require surgery. During surgery, the surgeon needs to make an incision in the skin on the inside of the finger to access the damaged tendon.\n\nA comparison will be done between two types of skin incisions in the fingers:\n\n* Bruner zig-zag incision\n* modified Bruner midlateral zig-zag incision\n\nResearch questions:\n\n* Is there a difference in pain between the types of incisions?\n* Is there a difference in swelling between the types of incisions?\n* Does the type of incision affect the final result in term of motion?\n\nPatients who will undergo surgery for a flexor tendon injury in a finger will be asked to participate and be randomized to one type of skin incision. All other parts of the surgery will be carried out as usual.\n\nAn occupational therapist and nurse will measure swelling and motion. The participant will report pain on a daily basis.\n\nThe results for pain, swelling, motion in the fingers and sensibility in the fingers will be statistically compared between the two types of incisions on a group level.\n\nThe results of this study may lead to guidelines for skin incisions in acute flexor tendon repair, allowing patients to experience less pain and swelling. This may facilitate the rehabilitation program and improve the final functional outcome.",[176,177],"Flexor Tendon Injury","Incision, Surgical",[179,180,181,182,183],"incision","Bruner","midlateral incision","flexor tendon","modified Bruner","2026-05-19",{"date":186,"type":39},"2026-05-22",{"date":131,"type":21},{"date":189,"type":21},"2028-06-01",{"name":45,"class":46},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":47},"100638327","safety-and-efficacy-of-eus-rfa-in-pancreatic-insulinoma-100638327","NCT07585032","Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma","EUSRFAINSU","Inclusion Criteria:\n\n* Insulinoma verified by pathology (often from EUS-FNB-sampling)\n\nExclusion Criteria:\n\n* Patients unwilling to participate\n* Patients unable to understand and obtain written informed conscent\n* Severe comorbidity","15 Years","80 Years",{"count":201,"type":21},20,"Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.\n\nIn the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.",[204],"Insulinoma; Pancreas",[206,207,208],"endosonography","insulinoma","radiofrequency ablation","2026-05-08",{"date":211,"type":39},"2026-05-13",{"date":213,"type":39},"2025-03-31",{"date":215,"type":21},"2029-06",{"name":45,"class":46},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":17,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":58,"phases":227,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100639338","phase-2-optimizing-aldosterone-receptor-antagonist-therapy-by-sodium-zirconium-cyclosili-cate-in-heart-failure--extension-opra-hf-extension-100639338","NCT07576257","OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)","OPRA-HF Extens","Inclusion Criteria:\n\n* 1\\. \\>70 yrs. 2. Regardless of LVEF but EF measured within past 2 years. For HFpEF echo criteria defined by ≥2 of: LV wall thickness ≥ 12 mm; LV mass index (BSA indexed LVH): male \\>115 g\u002Fm2, female \\>95 g\u002Fm2; relative wall thickness ≥0.42; E\u002Fe' ≥15 in sinus rhythm (or \\> 11 in the setting of atrial fibrillation); tricuspid regurgitation velocity \\>2.8 m\u002Fs; Left atrial volume index \\>34 ml\u002Fm2.\n\n  3\\. GFR ≥ 20 mL\u002Fmin\u002F1,73 m². 4. NYHA II-IV. 5. On optimal treatment as per physician´s judgement including ACE\u002FARB\u002FARNI, beta blockers, SGLT2 inhibitor för HFrEF\u002FHFmrEF, and SGLT2 inhibitors in HFpEF 6. Suboptimal treatment with MRA (defined as: no use or ≤ 25 mg daily 7. And one of following:\n  1. Prior hyperkalemia (S-K\\> 5.0 mmol\u002FL or P-K\\> 4.8 mmol\u002FL\\*) during MRA treatment within last 24 months, and current S-K ≤ 5.0 or P-K ≤ 4.8 mmol\u002FL\n  2. Current S-K 4.5-5.0 mmol\u002FL or P-K 4.3-4.8 mmol\u002FL, and potential risk of hyperkalemia as indicated by eGFR 30-45 ml\u002Fmin\u002F1,73 m2\n  3. Current S-K 5.1-5.9 mmol\u002FL or P-K 4.9-5.7 mmol\u002FL\n\n     * Corresponding plasma K (P-K) level is 0.2 mmol lower than serum K(S-K). Hyperkalemia is defined as P-K \\> 4,8 mmol\u002FL or S-K \\>5,0 mmol\u002FL.\n\n     Exclusion Criteria:","70 Years",{"count":226,"type":21},110,[228],"PHASE2","A multicenter, randomized, controlled study in Sweden (n=110). This study consists of 2 phases: 1) open-label run-in within approximately 2 months, and 2) randomized, double-blinded and placebo-controlled treatment for 6 months.\n\nThe open-label phase, in turn, consists of three periods: up-titration (normally 1 - 2 weeks, and longer in some cases), correction (maximum 72 hours) and maintenance (4 - 7 weeks).",[94],[232],"effect","2026-05-03",{"date":209,"type":39},{"date":236,"type":21},"2026-09-01",{"date":238,"type":21},"2030-06-30",{"name":45,"class":46},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":247,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":58,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100635449","trapeziometacarpal-joint-arthroplasty-versus-trapeziectomy-for-thumb-carpometacarpal-osteoarthritis-100635449","NCT07552831","Trapeziometacarpal Joint Arthroplasty Versus Trapeziectomy for Thumb Carpometacarpal Osteoarthritis","T3","Inclusion Criteria:\n\n* Pain at the base of the thumb affecting activities of daily living and insufficient response to at least 3 months of non-operative treatment (orthosis, non-steroidal anti-inflammatory drugs, and\u002For corticosteroid injections).\n* Radiographic thumb carpometacarpal osteoarthritis, Eaton grade 2-3.\n* For Eaton grade 2, age ≥50 years.\n* Age 18-69 years.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Symptomatic osteoarthritis of adjacent joints (e.g., scaphotrapeziotrapezoid joint, STT-joint).\n* Need for concurrent surgery in the metacarpophalangeal joint (e.g. arthrodesis or capsulodesis).\n* Post-traumatic thumb carpometacarpal osteoarthritis.\n* Previous surgery for thumb carpometacarpal osteoarthritis in the contralateral hand.\n* Inflammatory arthritis (e.g., rheumatoid arthritis or systemic lupus erythematosus).\n* Osteoporosis\u002Fosteopenia of such severity that secure cup placement in the trapezium is not possible (for arthroplasty).\n* Ongoing systemic corticosteroid treatment.\n* Other hand surgical condition in the same hand that could confound outcomes (e.g., carpal tunnel syndrome or de Quervain tenosynovitis).\n* Cognitive impairment preventing reliable participation.\n* Ongoing, or suspected ongoing, alcohol or drug misuse.\n* Insufficient Swedish language proficiency to complete the questionnaires.",true,{"count":249,"type":21},64,[60],"Thumb carpometacarpal osteoarthritis is common and may cause severe pain and functional limitation. Trapeziectomy is widely used, whereas prosthetic arthroplasty may offer faster early recovery. However, detailed information on early postoperative and long-term radiological outcomes remains limited.\n\nThis is a single-centre, blinded randomised controlled trial at Sahlgrenska University Hospital, Gothenburg, Sweden. Adults aged 18-69 years with symptomatic thumb carpometacarpal osteoarthritis (Eaton grade 2-3) refractory to at least 3 months of non-operative treatment will be randomised 1:1 to trapeziometacarpal prosthetic arthroplasty or trapeziectomy. The primary outcome is day-by-day pain (registration on a numeric rating scale NRS, 0-10). Secondary outcomes include day-by-day analgesic consumption for 90 days, orthosis use after cast removal, patient-reported function (HQ-8, QuickDASH, and Nelson score) at 30, 45, 60, 75 and 90 days, assessor-measured range of motion and strength at 45 and 90 days, and long-term clinical follow-up at 6 months and 1, 2, 5 and 10 years. Cone beam computed tomography will be obtained in the arthroplasty group at 1 week postoperatively as reference and at 6 months and 1, 2, 5 and 10 years to assess implant position, migration and loosening. The target sample size is 64 participants (32 per group), providing 95% power to detect a 1-point between-group difference on the pain scale. Analyses will follow the intention-to-treat principle.",[253],"Thumb Osteoarthritis","2026-04-30",{"date":256,"type":39},"2026-05-01",{"date":236,"type":21},{"date":259,"type":21},"2038-12-31",{"name":45,"class":46},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":288,"locationsCount":47},"100635198","antithrombin-as-a-predictor-of-heparin-resistance-in-cardiac-surgery-with-cardiopulmonary-bypass-100635198","NCT07549568","Antithrombin as a Predictor of Heparin Resistance in Cardiac Surgery With Cardiopulmonary Bypass","Inclusion Criteria:\n\n* Age ≥18 years\n* Planned cardiac surgery with cardiopulmonary bypass\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Emergency cardiac surgery\n* Ongoing antithrombin supplementation prior to surgery\n* Known severe congenital coagulation disorder affecting interpretation of outcomes\n* Severe liver failure\n* Missing key data required to define heparin resistance (e.g., missing heparin dose or ACT values)",{"count":268,"type":21},300,"This study aims to investigate whether the level of antithrombin (AT) in the blood before cardiac surgery can predict how well patients respond to heparin, a medication used to prevent blood clotting during surgery with a heart-lung machine (cardiopulmonary bypass).\n\nHeparin requires antithrombin to work effectively. Some patients have lower levels of antithrombin, which may result in reduced response to heparin, a condition known as heparin resistance. This can lead to difficulties achieving adequate anticoagulation during surgery and may require additional medication or adjustments in treatment.\n\nIn this study, an additional blood sample will be taken after anesthesia induction but before the administration of heparin. No changes will be made to the patient's treatment or care. Clinical data, including laboratory values, heparin dosing, and surgical outcomes, will be collected from routine medical records.\n\nThe goal is to identify a clinically useful antithrombin threshold that can help detect patients at risk of heparin resistance. This may improve patient safety, optimize treatment strategies, and reduce unnecessary use of antithrombin therapy in the future.",[271,98,100],"Heparin Resistance",[273,274,275,276,277,278,279,280,281,282],"Antithrombin","Antithrombin III","Heparin resistance","Activated clotting time","ACT","Cardiopulmonary bypass","Cardiac surgery","Anticoagulation","Heparin response","Predictive biomarker",{"date":284,"type":39},"2026-05-04",{"date":131,"type":21},{"date":287,"type":21},"2028-05-01",{"name":45,"class":46},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100618976","point-of-care-ultrasound-pocus-for-diagnosis-and-treatment-of-fractures-in-the-costal-cartilage-100618976","NCT07338617","Point of Care Ultrasound (POCUS) for Diagnosis and Treatment of Fractures in the Costal Cartilage","Inclusion Criteria:\n\n* Trauma patients (≥18 years) treated at the Department of Surgery, Sahlgrenska University Hospital, where CT has shown at least one recent injury to the chest wall.\n\nExclusion Criteria:\n\n* Patients with injuries resulting from CPR, severe head injury, spinal injury, and neurological or musculoskeletal disease affecting chest mobility will be excluded.",{"count":296,"type":21},100,"The goal of this observational study is to learn if combining ultrasound and CT scans can better diagnose cartilage fractures in the ribs, and to understand how finding these injuries affects treatment decisions for patients with injuries to the Chest wall.\n\nThe main questions it aims to answer are:\n\n* Does using both ultrasound and CT scans find more costal cartilage fractures than CT scans alone?\n* Does discovering costal cartilage fractures change how patients are treated, such as whether more patients receive surgery or if different fractures are repaired?\n* How do costal cartilage fractures heal, and do they affect lung function, pain, or the risk of complications after surgery?\n\nPatients with cartilage injuries will be followed up at 1, 3, and 12 months after their injury. They will be checked for pain, instability, and healing using ultrasound and sometimes CT scans. The study will also assess lung function, quality of life, and pain levels.",[299,300],"Rib Fracture","Cartilage Damage",[302,303,304,305],"Rib Fractures","Fractures, Cartilage","Ultrasonography","Traumatology","2026-04-27",{"date":133,"type":39},{"date":309,"type":21},"2026-06",{"date":311,"type":21},"2028-01",{"name":45,"class":46},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":58,"phases":320,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":47},"100618979","surgery-for-unstable-chest-wall-injuries---how-many-fractures-should-be-fixed-100618979","NCT07338656","Surgery for Unstable Chest Wall Injuries - How Many Fractures Should be Fixed?","Inclusion Criteria:\n\n* Patients scheduled for surgery of acute (≤7 days after trauma) unstable injuries in the chest wall at the Department of Surgery, Sahlgrenska University Hospital\n* Both parts of the unstable segment must be accessible for surgery.\n\nExclusion Criteria:\n\n* Patients with injuries resulting from CPR\n* Patients with severe head injury (Head AIS\\>3)\n* Patients with spinal injury\n* Patients with neurological or musculoskeletal disease affecting chest wall mobility.",{"count":296,"type":21},[60],"The goal of this prospective, randomized study is to learn about the effects of two different surgical techniques for treating unstable chest wall injuries in adults. The main questions it aims to answer are:\n\nDoes fixing two fractures per rib lead to better healing than fixing one fracture per rib in patients with unstable chest injuries? Does the choice of surgical method affect lung function, pain, other symptoms, risk of pneumonia, or the risk of complications?\n\nParticipants will:\n\n* Undergo surgery using either the standard method (fixing one fracture per rib) or an alternative method (fixing two fractures per rib), both using a muscle-sparing technique.\n* Be followed up at 1, 3, and 12 months after surgery.\n* Have CT scans at 3 months (and at 12 months if healing is incomplete) to assess bone healing.\n* Be evaluated for lung function, pain, symptoms, and complications.\n\nThis study aims to provide new knowledge about which surgical method is best for unstable chest wall injuries, helping to improve treatment and recovery for these patients.",[323,324],"Rib Fracture Multiple","Flail Chest",[302,324,305,326],"Comparative Study",{"date":133,"type":39},{"date":329,"type":21},"2026-05-05",{"date":331,"type":21},"2028-12",{"name":45,"class":46},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":58,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":47},"100472470","preventive-physical-activity-intervention-in-head-and-neck-cancer-100472470","NCT05432297","Preventive Physical Activity Intervention in Head and Neck Cancer","Preventive Randomized Study Regarding Physical Activity Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer: the Effect of Preventive Intervention for Physical Activity, Function and Quality of Life","Inclusion Criteria:\n\n* Head and neck cancer (tumors of the oropharynx, pharynx, hypopharynx and larynx)\n* Receiving radiohterapy (+\u002F- chemotherapy) with curative intent\n\nExclusion Criteria:\n\n* Surgery due to head and neck cancer\n* Previous treatment for head and neck cancer\n* Tracheostomized patients\n* Inability to perform exercise intervention\n* Inability to perform part of 6-minute walking test\n* Inability to independently fill out questionnaires in Swedish\n* Previous neurologic or neuromuscular disease",{"count":84,"type":21},[60],"The study includes patients with tumors of the oropharynx, larynx and hypopharynx scheduled to receive radiotherapy with curative intent (+\u002F- chemotherapy). The patients will be randomized into either an intervention group (performing a preventive physical activity protocol before and during radiotherapy) or a control group not performing a specified physical exercise protocol. All patients will be in contact with with a speech language pathologist or a physical therapist weekly during radiotherapy. The study is expected to improve physical function and quality of life during and after oncologic treatment",[344,345],"Head and Neck Neoplasms","Physical Inactivity","2026-04-22",{"date":348,"type":39},"2026-04-23",{"date":350,"type":39},"2023-01-02",{"date":352,"type":21},"2032-12",{"name":45,"class":46},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":362,"conditions":363,"keywords":365,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":163},"100502129","satisfaction-and-recovery-after-distal-radius-fracture-100502129","NCT05818241","Satisfaction and Recovery After Distal Radius Fracture","Study on the Immediate Recovery and Satisfaction After Distal Radius Fracture During the First Three Months- a PROM Based Observational Study With Day-to-day Records","Inclusion Criteria:\n\n* Unilateral distal radius fractures in patients without any other significant injuries regardless of ligament injuries and ulnar fractures.\n* Signed written consent\n\nExclusion Criteria:\n\n* Compound injuries\n* Open fractures\n* Patients with post traumatic function deficits at any level in the affected arm prior to the distal radius fracture.\n* Patients with function deficits in the affected arm due to other medical conditions (e.g. Parkinsons disease, Rheumatoid Arthritis)\n* Reduced mental capacity (e.g. dementia, substance abuse)",{"count":268,"type":21},"Distal radius fracture is the most common fracture in Sweden, but little is known about the patient's experience of pain and hand function during the first three months after the injury. This observational study will provide detailed information on a daily basis regarding pain, use of analgesic drugs, use of splints and hand function as measured weekly by a condition-specific questionnaire.",[364],"Distal Radius Fracture",[366,367],"wrist function","recovery","2026-04-21",{"date":370,"type":39},"2026-04-24",{"date":372,"type":39},"2023-01-12",{"date":374,"type":21},"2028-04-01",{"name":45,"class":46},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":386,"conditions":387,"keywords":393,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":412},"100630701","repeated-examinations-for-typing-pulmonary-embolism-100630701","NCT07491094","Repeated Examinations for Typing Pulmonary Embolism","Repeated Examinations for Typing Pulmonary Embolism (RE-TyPE)","RE-TyPE","Inclusion Criteria:\n\n1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital\n2. Written informed consent\n\nExclusion Criteria from Cohort A:\n\n1. Low risk, intermediate-low risk or high risk PE\\*\n2. \\>48 hours since arrival to hospital\n3. Expected inability to comply with the protocol (e.g. dementia)\n\nThere are no exclusion criteria from Cohort B. Patients in Cohort B who are not part of Cohort A may be included at diagnosis (day 0) or at follow-up (\\~day 90).\n\n\\*If biomarkers (and\u002For echocardiography) are not available in hemodynamically stable patients, RV\u002FLV-ratio \\>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B",{"count":385,"type":21},400,"PURPOSE\n\nThe two related purposes of the RE-TyPE study are:\n\n1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and\n2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital\n\nHYPOTHESES\n\n1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome\n2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital",[388,389,390,391,392],"Pulmonary Embolism (Diagnosis)","Pulmonary Embolism Acute","Pulmonary Embolism With Acute Cor Pulmonale","Pulmonary Embolism With Right Ventricle Enlargement","Pulmonary Embolism (PE)",[394,395,396,397,398,399,400,401,402,403],"Echocardiography","Point Of Care UltraSound (POCUS)","Electrocardiography (ECG)","Biomarkers\u002FBlood","Troponin I","NT-pro-BNP","Lactate","Prediction model","Clinical deterioration","Death","2026-04-02",{"date":406,"type":39},"2026-04-06",{"date":408,"type":39},"2026-04-01",{"date":410,"type":21},"2032-01-01",{"name":45,"class":46},3,{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":421,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":58,"phases":424,"briefSummary":425,"conditions":426,"keywords":432,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":47},"100631306","primary-rplnd-versus-systemic-chemotherapy-in-good-prognosis-metastatic-testicular-cancer-100631306","NCT07498959","Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer","Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease","TESTIGO","Inclusion Criteria:\n\n* Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A\u002FB (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)\n\nExclusion Criteria:\n\n* Previous chemotherapy (including adjuvant chemotherapy at diagnosis)\n* Previous RPLND\n* Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires","MALE",{"count":423,"type":21},160,[60],"The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is:\n\nDoes primary RPLND lower the risk of side-effects compared to receiving chemotherapy?",[427,428,429,430,431],"Testicular Cancer","Seminoma","Quality of Life","De-escalation","RPLND",[433,434,435],"testicular cancer","seminoma","primary RPLND","2026-03-24",{"date":438,"type":39},"2026-03-27",{"date":440,"type":39},"2026-03-19",{"date":442,"type":21},"2032-03-25",{"name":45,"class":46},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":451,"maxAge":4,"enrollmentInfo":452,"targetDuration":454,"studyType":22,"phases":4,"briefSummary":455,"conditions":456,"keywords":459,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":412},"100601886","late-onset-seizures-trial-of-vascular-risk-investigation-and-treatment-100601886","NCT07116330","Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment","LOSTIT","Inclusion Criteria\n\nClinical study:\n\n\\- First assessment for unprovoked seizures or epilepsy with onset after age 50 -- - vascular risk factor evaluation per the new routine at participating care givers\n\nRegister study:\n\n* age ≥50 with a first-ever outpatient appointment to one of the participating clinics and\n* a first-listed diagnostic code for seizures or epilepsy (ICD-10: R568, G40)\n\nExclusion Criteria\n\nClinical study:\n\n* Inability to consent.\n* Progressive brain disease (tumour or degenerative)\n\nRegister study:\n\n* preexisting seizures\u002Fepilepsy, as demonstrated by a registered diagnostic code for seizures (ICD-10: R568, G40, G41) or a dispensed antiseizure medication (ATC-code: N03) more than 3 months before the initial consultation\n* a registered diagnostic code for stroke or TIA (ICD-10: I61, I63, I64, or G45 except G454) before the initial consultation, or\n* progressive brain disease, as indicated by diagnostic codes or drug prescriptions suggestive of brain tumors (ICD-10: C71, D33, D43, C793) or\n* neurocognitive disorders (ICD-10: F00-F03, F051, G30, G318, G912; ATC code: N06D).","50 Years",{"count":453,"type":21},420,"5 Years","A growing body of evidence suggests patients with late-onset seizures are at an increased risk of stroke, but the potential for reducing cardiovascular morbidity through risk factor screening and management is unknown.\n\nThe investigators aim to determine whether individuals with new-onset unprovoked seizures after middle age should undergo vascular risk assessment. In a cluster project the investigators assess the effect of vascular risk factor screening in an observational study as well as a cohort study.\n\nThe project has two interlinked components: a prospective single group study, in which risk factor assessment is performed and subsequent management is followed for one year; and a register-based cohort study examining the long-term effects of the intervention on a system level.",[457,458],"Epilepsy","Seizure",[460,461],"vascular risk","cardiovascular","2026-02-27",{"date":464,"type":39},"2026-03-03",{"date":466,"type":39},"2025-09-01",{"date":468,"type":21},"2035-06",{"name":45,"class":46},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":497},"100593223","reperfusion-treatment-in-acute-pulmonary-embolism-100593223","NCT07003646","Reperfusion Treatment in Acute Pulmonary Embolism","Reperfusion Treatment in Acute Pulmonary Embolism: A Multicenter Observational Study in the Nordic Countries","PE-NORDIC","Inclusion Criteria:\n\n* All adult patients (≥18 years), including pregnant women, with verified (CTPA, angiography or scintigraphy) acute pulmonary embolism who are planned for, or have received, treatment with catheter directed intervention or systemic thrombolysis\n* Informed consent (for patients who do not survive before informed consent can be obtained, a waiver of consent applies)\n\nExclusion Criteria:\n\n* Ongoing enrolment in interventional catheter directed intervention trial\n* Surgical embolectomy as primary reperfusion treatment",{"count":479,"type":21},220,"International guidelines recommend immediate reperfusion with systemic thrombolysis (ST) as first-line treatment in high-risk pulmonary embolism (PE). The therapy improves hemodynamics and overall survival but is also associated with a significant risk of severe bleeding. Catheter-directed intervention (CDI) is recommended as an alternative reperfusion therapy in high-risk PE when ST is contraindicated or has failed, as well as in patients who deteriorate or fail to improve during anticoagulation (AC) treatment. Despite lack of high-quality evidence and randomized studies between CDI and standard care, the use of CDI is spreading rapidly in high-risk PE and in less severe PE not fulfilling current treatment criteria.",[482],"Pulmonary Embolism",[484,485,486,487,488],"Thrombolysis","Catheter-directed intervention","Aspirational thrombectomy","Catheter-directed tromboylsis","High-risk PE","2026-01-18",{"date":491,"type":39},"2026-01-21",{"date":493,"type":39},"2025-04-01",{"date":495,"type":21},"2029-05-01",{"name":45,"class":46},13,{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":504,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":47},"100377765","predictors-for-survival-and-good-neurological-outcome-in-e-cpr-and-non-cpr-treated-patients-100377765","NCT04198792","Predictors for Survival and Good Neurological Outcome in E-CPR and Non CPR Treated Patients","Inclusion Criteria:\n\n* ECMO-treated patients.\n\nExclusion Criteria:\n\n* None","16 Years",{"count":20,"type":21},"In ECPR, where CPR times often range from 30 to 120 minutes, only patients with good circulation during CPR survive, while non-survivors commonly suffer from anoxic brain injury. The selection process during CPR is challenging causing a general survival rate of just 2 out of 10, and the urgent need for better selection criteria has been emphasized. It it crucial to keep cardiac arrest times as short as possible, pre primed-ECMO can facilitate this.\n\nThe ECMO treatment and the long CPR times of ECPR can also affect the measurements of the neurologic prognostication guidelines after cardiac arrest, making its validity uncertain in this specific cohort. Further, the long-term neuropsychological follow-up is limited to a few patients, making it uncertain if ECPR gives the survivors good long-term life satisfaction or just a prolonged life.\n\nOur overall aim is to optimize and improve the care pathway for ECPR patients by refining patient selection, assessing pre-primed ECMO, validating neurological prognostication guidelines, and understanding long-term outcomes and challenges faced by survivors.\n\nSpecific Aim 1: Evaluating predictors for good neurological outcomes in ECPR and to develop and validate (internally and externally) an evidence-based selection tool for ECPR.\n\nSpecific aim 2: To assess the sterility and function of pre-primed ECMO.\n\nSpecific aim 3: To evaluate the applicability of current guidelines for neurological prognostication after cardiac arrest in ECPR patients, and to assess the predictive value of individual and combined neurological tests in this specific patient population.\n\nSpecific aim 4: To determine the long-term neuropsychological outcomes, identify the problems survivors experience in daily life, and assess life satisfaction - by comprehensive follow-up visits with validated questionnaires and neuropsychology testing up to 12 years after the ECMO-treated cardiac arrest.",[508,509,510],"Cardiac Arrest","Extracorporeal Membrane Oxygenation","Hypoxia-Ischemia, Brain","2026-01-14",{"date":513,"type":39},"2026-01-20",{"date":515,"type":39},"2010-01-01",{"date":517,"type":21},"2030-01-01",{"name":45,"class":46},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":527,"enrollmentInfo":528,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":47},"100521467","using-machine-learning-and-biomarkers-for-early-detection-of-delayed-cerebral-ischemia-100521467","NCT06069973","Using Machine Learning and Biomarkers for Early Detection of Delayed Cerebral Ischemia","Machine Learning and Biomarkers for Early Detection of Delayed Cerebral Ischemia","CIDAIBASSAH","Inclusion Criteria:\n\nPatients over the age of 18 with aneurysmal subarachnoid hemorrhage admitted to intensive care units at Sahlgrenska University hospital.\n\nExclusion Criteria:\n\n* Unable to consent,\n* Cardiac arrythmia,\n* Previous brain damage","110 Years",{"count":529,"type":21},1500,"The overall goal of this project is to determine if machine learning and analysis of neurospecific biomarkers can enable early detection of upcoming or ongoing cerebral ischaemia in patients suffering from subarachnoid haemorrhage with altered consciousness due to cerebral injury or sedation. Analyses of heart rate variability, electroencephalgraphy,nearinfrared spectroscopy, cerebral autoregulation, and brain injury specific biomarkers in blood and cerebrospinal fluid will be performed.",[532,533],"Ischemic Stroke","Hemorrhagic Stroke","2026-01-08",{"date":536,"type":39},"2026-01-12",{"date":538,"type":39},"2024-01-01",{"date":540,"type":21},"2033-12-31",{"name":45,"class":46},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":247,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":550,"targetDuration":454,"studyType":22,"phases":4,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":47},"100619471","western-sweden-systemic-sclerosis-project-100619471","NCT07345052","Western Sweden Systemic Sclerosis Project","Western Sweden Systemic Sclerosis Project - A Study on Underlying Mechanisms for Disease Development and Predictors of Disease Activity and Treatment Response in Patients With Systemic Sclerosis","WESST","Inclusion Criteria:\n\n* Participants diagnosed with SSc according to the ACR and EULAR classification criteria\n\nExclusion Criteria:\n\n* Diagnosis of Mixed connective tissue disease\n* Not speaking or reading Swedish\n* With severe cognitive impairment\n* With blood count below specified limits\n* Allergy to local anaesthetic (for subjects who will provide a skin biopsy)",{"count":551,"type":21},150,"The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment options. A cohort of patients with SSc will be collected at the Sahlgrenska University Hospital in Gothenburg, Skaraborg Hospital in Skövde, and Södra Älvsborg Hospital in Borås (Sweden). Thanks to a holistic approach including integrated analysis of blood, and skin samples as well as DNA, and with the use of state-of-the-art methods, this project aims to identify factors (e.g. genes, proteins, metabolites, and immune cell types) associated with the development of SSc and with the progression to a more aggressive phenotype. Functional studies using in vitro model systems and patient specimens will be also implemented. The findings of the current project could lead to the identification of possible diagnostic and prognostic markers for the disease as well as potential drug targets. This cohort will be also linked to the European Scleroderma Trial and Research (EUSTAR), which is an international SSc research network aiming to coordinate research activities on SSc from groups all over Europe in order to improve treatment, quality of life and mortality of patients with SSc.",[554,555,556,557],"Scleroderma, Systemic","Fibrosis; Skin","Fibrosis Lung","Interstitial Lung Disease Due to Systemic Disease","2026-01-07",{"date":560,"type":39},"2026-01-15",{"date":562,"type":39},"2022-06-20",{"date":564,"type":21},"2030-12-31",{"name":45,"class":46},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":47},"100616559","prediction-model-for-the-risk-of-developing-foot-ulcers-in-diabetes-100616559","NCT07307183","Prediction Model for the Risk of Developing Foot Ulcers in Diabetes","Inclusion Criteria:\n\n* Adult patients aged 18 years or older at the time of inclusion\n* Patients with a diagnosis of diabetes mellitus according to ICD-10 codes E10-E14, and\u002For\n* Patients who have been prescribed at least one diabetes-related medication after the age of 18\n* Patients with relevant diagnoses and\u002For prescriptions recorded in the study data sources between 1 January 2014 and 30 June 2025\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age at the time of diabetes diagnosis or prescription\n* Patients with no recorded diagnosis of diabetes (ICD-10 E10-E14) and no prescription of diabetes medication after the age of 18\n* Patients with incomplete or missing key data required for model development or validation (e.g. missing outcome or essential covariates)",{"count":573,"type":21},100000,"Introduction Foot ulcers in diabetes mellitus (DM) are a common and serious complication that can lead to infection, amputation, and increased mortality. Early identification of patients at high risk is crucial in order to implement preventive measures at an early stage. The number of people with DM is increasing globally, from 540 million in 2021 to an estimated 780 million by 2045. Foot ulcers cause considerable suffering for the individual and entail substantial costs for the healthcare system.\n\nDespite national guidelines recommending regular, structured foot examinations and risk classification to assess the risk of developing foot ulcers, current risk models do not take into account the complex interactions between risk factors and socioeconomic factors such as marital status, level of education, and place of residence.\n\nData-driven advances and artificial intelligence (AI) offer new opportunities to refine risk identification, but their use in predicting the risk of diabetic foot ulcers remains limited. The need for foot screening is considerable. In Sweden, there are approximately 600,000 patients with DM, and half of them live with an increased risk due to nerve damage in the feet. This means that, based on risk level, around 300,000 patients in Sweden may require preventive interventions, including medical foot care, customised footwear, and access to specialist care for those with foot ulcers. Improved preventive efforts are emphasised in the person-centred and integrated care pathway for people with diabetes at high risk of foot ulcers. However, accurate identification of foot ulcer risk is currently lacking.\n\nPrevention leads not only to good quality of life for the individual but also to reduced healthcare costs. Estimates by Ragnarsson Tennvall show that a hard-to-heal ulcer costs approximately SEK 100,000 per year, while an amputation costs around SEK 300,000-500,000. Given a prevalence of foot ulcers of 5% among patients with diabetes, the annual cost of ulcer care amounts to SEK 3 billion. In addition, there are costs of approximately SEK 750 million for amputations, according to data from the quality register SwedAmp.\n\nThe aim of the study is to develop, test, and validate prediction models (statistical and AI-based) to identify patients with DM who are at risk of developing foot ulcers. The models will be based on retrospective electronic health record data from primary care in the Västra Götaland Region (VGR), as well as data from Statistics Sweden (SCB) concerning demographic factors such as marital status, level of education, occupation, and place of residence.\n\nMethods The study has two methodological approaches: AI-based modelling and statistical modelling.\n\nAI-based approach Machine learning models will be developed to predict patients at risk of developing diabetic foot ulcers. The models will be trained using cross-validation on a large dataset in which variables will be iteratively excluded. Conformal prediction will be used to quantify uncertainty in patient-level predictions. The resulting models will be analysed to identify the strongest predictors and will be compared with classical statistical modelling and findings from the literature.\n\nSteps in AI modelling:\n\nData extraction: Electronic health record data from primary care in VGR, supplemented with sociodemographic data from SCB.\n\nData processing: Use of, among other variables, diagnostic codes (ICD-10), healthcare interventions (KVÅ codes), visit types, visit frequency, ECG parameters, and free-text data to construct predictors.\n\nModel development: Prediction models will be developed and trained using cross-validation. Measures of uncertainty will be generated using conformal prediction.\n\nValidation: A separate cohort will be used to test model performance (sensitivity, specificity, positive predictive value \\[PPV\\]).\n\nInterpretation: The models will be reviewed for transparency and clinical interpretability in collaboration with patient representatives, clinicians, and researchers.\n\nThe results of the statistical and AI-based models will be compared with regard to their respective strengths and weaknesses.\n\nStatistical modelling Two populations will be analysed: patients with diabetes without foot ulcers and patients with diabetes with foot ulcers. Co-variation and causal relationships between risk factors and foot ulcers will be identified. A model describing causal pathways leading to ulcer development will be developed, and its certainty and uncertainty will be analysed.",[576],"Diabete Mellitus",[578,579,580,581,582],"Cohort","Retrospective","diabetic foot","foot ulcer","artificial intelligence","2025-12-14",{"date":585,"type":39},"2025-12-29",{"date":587,"type":39},"2014-01-30",{"date":589,"type":21},"2027-12-30",{"name":45,"class":46},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":224,"enrollmentInfo":599,"targetDuration":4,"studyType":58,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":620},"100561044","placebo-effect-in-spinal-cord-electrical-stimulation-for-pain-100561044","NCT06585033","Placebo Effect In Spinal Cord Electrical Stimulation for Pain","Spinal Cord Stimulation for the Treatment of Therapy-Resistant Neuropathic Pain After Lumbar Spinal Surgery - A Randomized, Double-Blind, Sham-Controlled, Cross-over Study","PISCES","Inclusion Criteria:\n\n* History consistent with PSPS2 of at least 6 months after the last spinal surgery. The patient experienced no effect of conservative treatments and has been assessed as not eligible for further spinal surgery.\n* Patients between 18-70 years of age.\n* Average perceived pain intensity in one or both legs of 5 or more and average perceived pain intensity in the back of less than 3 measured with the validated 11-box NRS (0 no pain, 10 worst imaginable pain)\n* The patient should have been informed verbally and in writing about the study and should have provided informed written consent to participate.\n* Adequate pain relief effect (50% or more) after a two week trial with active test stimulation.\n\nExclusion Criteria:\n\n* Subject is unable to understand or operate the SCS device.\n* Subject currently has an active implantable device including pacemakers, spinal cord stimulator or intrathecal drug delivery system.\n* Ongoing coagulation disorder.\n* Ongoing abuse of alcohol, drugs, or prescription opioids.\n* Active debilitating psychiatric illness.\n* Active malignancy.\n* Condition with increased general infection sensitivity, such as known immunodeficiency.\n* Expected lifespan \\<1 year.\n* Ongoing local infection or other skin disease where the IPG is planned to be placed.\n* Pregnancy.",{"count":600,"type":21},50,[60],"Objective: To evaluate if spinal cord stimulation (SCS) performs better than placebo (no stimulation) in the long term to reduce persistent neuropathic leg pain refractory to medication and other conservative treatments in patients who have undergone lumbar spinal surgery.\n\nStudy design: Multicenter, double blind, randomized, sham-controlled trial.\n\nAfter a positive SCS test trial, participants (18-70 years) will be implanted with a non-rechargeable SCS system providing active, subthreshold stimulation and followed for 12 months in a blinded cross-over design. The primary outcome measure is the difference in change in leg pain intensity scores using the Numeric Rating Scale (NRS) between a 3-month period with optimized subthreshold stimulation, and a 3-month period with no stimulation, as compared to baseline. Quality of life, physical functioning, sleep quality, return to work, and reduction in medication use will also be investigated.\n\nBackground: Up to 20% of patients who have undergone lumbar spinal surgery experience persistent back\u002Fleg pain leading to long-term reduction in functionality and quality of life. SCS is an established and safe, minimally invasive treatment for these patients when no further surgery is indicated and conservative therapies have been found to be ineffective. Placebo-controlled studies, comparing active and sham stimulation, were lacking until recently as traditional SCS relied on the patient feeling the stimulation (paresthesia). Technological progress with development of paresthesia-free stimulation forms now allows for the execution of placebo-controlled studies. A recent trial showing no significant difference in long-term effectiveness between active SCS and sham suffers from significant methodological shortcomings. This necessitates further sham-controlled studies to determine the effectiveness of SCS.",[604],"Chronic Postoperative Pain",[606,607,608,609,610,611],"Spinal cord stimulation","Lumbar spine surgery","Chronic pain","Pain reduction","Placebo","Randomized controlled trial","2025-11-24",{"date":614,"type":39},"2025-12-02",{"date":616,"type":39},"2024-11-15",{"date":618,"type":21},"2027-06-30",{"name":45,"class":46},4,{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":451,"maxAge":628,"enrollmentInfo":629,"targetDuration":4,"studyType":58,"phases":631,"briefSummary":632,"conditions":633,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":641,"locationsCount":47},"100522041","comparative-analysis-of-ai-software-for-enhanced-polyp-detection-and-diagnosis-100522041","NCT06077435","Comparative Analysis of AI Software for Enhanced Polyp Detection and Diagnosis","Comparative Analysis of AI Software and Conventional Colonoscopy for Enhanced Polyp Detection and Diagnosis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\> 50 years\n* Elective colonoscopy\n\nExclusion Criteria:\n\n* Patient declines to participate in the study.\n* Age \\\u003C 50 years\n* Unprepared bowel","90 Years",{"count":630,"type":21},915,[60],"Purpose \\& Research Questions\n\nThe purpose of this study is to evaluate whether artificial intelligence (AI) improves the detection of polyps and whether the system can classify the type and severity of detected changes. The investigators will also assess if there are any differences between the various AI systems and whether the polyps that may be missed are benign or malignant.",[634,635],"Colonic Polyp","Colon Lesion","2025-11-19",{"date":612,"type":39},{"date":639,"type":39},"2023-03-01",{"date":131,"type":21},{"name":45,"class":46},{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":649,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":650,"conditions":651,"keywords":654,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":660,"leadSponsor":662,"locationsCount":47},"100609223","comparison-of-transcutaneous-and-arterial-carbon-dioxide-sampling-during-jet-ventilation-a-prospective-study-on-patients-undergoing-percutaneous-liver-tumour-radiofrequency-ablation-100609223","NCT07211763","Comparison of Transcutaneous and Arterial Carbon Dioxide Sampling During Jet Ventilation, a Prospective. Study on Patients Undergoing Percutaneous Liver Tumour Radiofrequency Ablation","Transcutaneous Versus Arterial Carbon Dioxide Monitoring During Jet Ventilation","Inclusion Criteria:\n\n* adult patients undergoing percutaneous RF liver tumour ablation requiring jet ventilation\n\nExclusion Criteria:\n\n* disease or condition. not compatible with jet ventilation",{"count":296,"type":21},"The study aims to compare the readings from two methods of monitoring carbon dioxide levels during jet ventilation when normal end-tidal monitoring is not possible. During jet ventilation it is technically not possible to monitor the levels of carbon dioxide in exhaled air as is the standard in preoperative care. We will compare transcutaneous (through the skin) monitoring to an arterial blood. sample. Both transcutaneous monitoring and arterial monitoring is currently used as the standard for this patient group at our institution. By collecting data prospectively we can evaluate if there. are discrepancies based on monitoring method. All patients will be treated per standard preoperative protocol and only patients consenting to participate will contribute data to the comparison and statistical analysis.",[652,653],"Liver Ablation","High Frequency Jet Ventilation",[655],"jet ventilation","2025-10-01",{"date":658,"type":39},"2025-10-08",{"date":493,"type":39},{"date":661,"type":21},"2026-07",{"name":45,"class":46},""]